An evaluation of bimekizumab for the treatment of hidradenitis suppurativa

This is the authors' abstract. We don't add key points for this paper.

INTRODUCTION: Until recently, the biological treatment options for hidradenitis suppurativa (HS) were largely restricted to adalimumab and secukinumab. In 2024, bimekizumab, an IL-17A and IL-17F antibody was introduced to the clinical practice. AREAS COVERED: Bimekizumab offers a new therapeutic approach for managing HS. It was approved by the U.S Food and Drug Administration (FDA) and European Medicines Agency (EMA) in 2024. The available biologic therapies in HS treatment are described. The data from phase II and phase III clinical trials were analyzed to evaluate the bimekizumab effectiveness in HS treatment. Data from those trials and latest summaries of product characteristics (SmPC) were retrieved to investigate its safety profile. The current preliminary data regarding its long-term effectiveness from BE HEARD EXT (NCT04901195) trial were presented. EXPERT OPINION: The common side effects of bimekizumab were upper respiratory infections, candida infections and eczematous reactions across all indications. The favorable side effects profile and strong clinical effectiveness proved in clinical trials gave the bimekizumab potential to become the first-choice drug in HS treatment.